For malignancy detection, SMAD4/TP53 mutation detected in pancreatic fluid can distinguish PDAC from IPMN cases, with a 32.4% sensitivity and 100% specificity [54]. This evidence concerns the gene TP53 and pancreatic intraductal papillary-mucinous neoplasm.